Treatment of Attention Deficit Hyperactivity Disorder in Preschool-Age Children (PATS)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00018863 |
Recruitment Status :
Completed
First Posted : July 9, 2001
Last Update Posted : December 2, 2020
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Attention Deficit Disorder With Hyperactivity | Drug: Methylphenidate | Phase 3 |
Study Type : | Interventional (Clinical Trial) |
Enrollment : | 165 participants |
Allocation: | Randomized |
Masking: | Double |
Primary Purpose: | Treatment |
Official Title: | Methylphenidate Efficacy and Safety in ADHD Preschoolers |
Actual Study Start Date : | April 1, 2001 |
Actual Primary Completion Date : | March 31, 2006 |
Actual Study Completion Date : | November 30, 2006 |


Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 3 Years to 5 Years (Child) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Boys and girls who are:
- Between the ages of 3-5.5 years
- Qualified as having ADHD by our diagnostic evaluations and clinical staff
- Otherwise generally healthy
- Willing, and have parents that are willing, to attend all visits required by the study
- Enrolled in some type of day-program: day care, preschool, nursery school, kindergarten, for at least 2 half days/week
- In classrooms with teachers that are willing to participate by completing rating scale

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00018863
United States, California | |
University of California, Irvine | |
Irvine, California, United States | |
University of California, Los Angeles | |
Los Angeles, California, United States | |
United States, Maryland | |
Johns Hopkins University | |
Baltimore, Maryland, United States | |
United States, New York | |
New York State Psychiatric Institute | |
New York, New York, United States | |
New York University School of Medicine | |
New York, New York, United States | |
United States, North Carolina | |
Duke University Medical Center | |
Durham, North Carolina, United States |
Study Chair: | Laurence Greenhill, M.D. |
Publications of Results:
Other Publications:
Responsible Party: | Laurence Greenhill, Professor of Clinical Child and Adolescent Psychiatry, New York State Psychiatric Institute |
ClinicalTrials.gov Identifier: | NCT00018863 |
Other Study ID Numbers: |
#3761 U01MH060903 ( U.S. NIH Grant/Contract ) U01MH060642 ( U.S. NIH Grant/Contract ) U01MH060943 ( U.S. NIH Grant/Contract ) U01MH060848 ( U.S. NIH Grant/Contract ) U01MH060900 ( U.S. NIH Grant/Contract ) U01MH060833 ( U.S. NIH Grant/Contract ) DSIR CT-M2 |
First Posted: | July 9, 2001 Key Record Dates |
Last Update Posted: | December 2, 2020 |
Last Verified: | November 2020 |
ADHD |
Hyperkinesis Attention Deficit Disorder with Hyperactivity Attention Deficit and Disruptive Behavior Disorders Neurodevelopmental Disorders Mental Disorders Dyskinesias Neurologic Manifestations Nervous System Diseases Methylphenidate |
Central Nervous System Stimulants Physiological Effects of Drugs Dopamine Uptake Inhibitors Neurotransmitter Uptake Inhibitors Membrane Transport Modulators Molecular Mechanisms of Pharmacological Action Dopamine Agents Neurotransmitter Agents |